Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
No details shared by TauRx on the RFIs by UK MHRA. However, one of the request is probably the peer reviewed clinical trial results for hmtm judging from the press release by TauRx back in end of Jan'26
it is probably due to lack of understanding on the particular topic, yap sk. the process is uk mhra has to grant approval first and then, NICE or the technology appraisal committee will then review and decide whether it is suitable for use by NHS UK.
You can click on the link below and scroll down to the bottom of the page which will show the following remarks. The "regulatory" here is referring to UK MHRA - The committee meeting planned for 12 February 2025 will be rescheduled and the timelines for this appraisal will be revised to ensure they align with regulatory timings. We will provide a further update when it is available. https://www.nice.org.uk/guidance/indevelopment/gid-ta11379
There will be foreign exchange gain, Vin. USD weakened / MYR strengthened by approx 5% in q4'25 comparing to q3'25 peak and approx 10% comparing to q4'24 peak. The forex gain/loss will not move the share price as can be seen from the past reports. SG, MY and US assets performance trends will have a bigger impact on the share price.
There are 2 more variables added into the performance factors in 2026 onwards - (1) The 3.0 bil MTN issued this year for the financing of GenM acquisition at 3 months KLIBOR + 1.80 pc interest (~5.2 pc per annum) means additional 40 mil qtrly finance cost added; excluding any redemption this year onwards (2) Increasing GenM stakes from 49 pc to 73.8 pc means higher profit/loss attributable to equity holders and lower NCI.
